John Walden's questions to Crinetics Pharmaceuticals Inc (CRNX) leadership • Q2 2025
Question
An analyst on behalf of John Walden from Citizens JMP requested more color on the potential endpoints for the Cushing's disease trial and how they might differ for adamelin's mechanism versus other approved drugs.
Answer
Chief Endocrinologist Alan Krasner explained that the primary endpoint is typically normalization of 24-hour urine free cortisol (UFC). He highlighted that adamelin is uniquely situated due to the unprecedented rapidity of UFC normalization seen in trials so far, with patients achieving normalization in less than ten days. He expressed excitement to see if this consistent finding holds in larger, longer trials.